PepGen

Q3 FY2026 EarningsQ3 FY26 results for the clinical-stage biotech were largely in line with consensus on the bottom line, despite the company having no revenue as expected. GAAP EPS of -$0.28 vs. -$0.27 mean expected reflects consistent R&D investment in the PGN-EDODM1 program following the discontinuation of the DMD pipeline. Net loss of $19.4M was slightly wider than the $19.3M consensus, while the cash position of $104.8M remains sufficient to fund operations into 2028, according to management guidance.